Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis's Entresto Clears NICE But It’s a Close Run Thing

Executive Summary

The innovative nature of Novartis's new chronic heart failure therapy Entresto counted towards NICE's appraisal committee clearing its use in Britain's National Health Service, despite a cost-effectiveness ratio that was close to the upper limit for gaining a positive recommendation.

You may also be interested in...

Novartis's Entresto Doesn't Impress In 1Q; Orphan Drug Fails In PhIII

Novartis AG's newly launched heart failure drug Entresto (valsartan/sacubitril), which has been dubbed the company's next blockbuster product, missed the mark in the first quarter of the year, posting sales more than $10m below analyst forecasts.

IQWiG: Added Benefit Not Proven For Elocta, But Entresto Sails Through

Swedish Orphan Biovitrum AB (Sobi) is preparing to respond to an "added benefit not proven" decision on its long-acting recombinant Factor VIII product Elocta (efmoroctocog) from Germany's HTA body, IQWiG, a negative ruling that the company was expecting. The response will be submitted by April 22, just before a scheduled oral meeting with IQWiG in May, with a final decision by the top HTA body, the Federal Joint Committee (G-BA), expected later this year.

Pipeline Watch: Phase III Readouts For Seladelpar, Fasinumab And Carbetocin

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts